Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

Maya Buch

doi:10.1136/ard-2022-223406

Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

Maya Buch

Division of Musculoskeletal & Dermatological Sciences (L5)

Research output: Contribution to journal › Letter › peer-review

2 Downloads (Pure)

Original language	English
Pages (from-to)	575-577
Number of pages	2
Journal	Annals of Rheumatic Diseases
Volume	82
Issue number	4
Early online date	31 Jan 2023
DOIs	https://doi.org/10.1136/ard-2022-223406
Publication status	Published - 1 Apr 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/ard-2022-223406

ard-2022-223406.full

Cite this

@article{2f9d6daeaa824f25884f19d47d3d6587,

title = "Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme",

author = "Maya Buch",

year = "2023",

month = apr,

day = "1",

doi = "10.1136/ard-2022-223406",

language = "English",

volume = "82",

pages = "575--577",

journal = "Annals of Rheumatic Diseases",

issn = "0003-4967",

publisher = "Elsevier BV",

number = "4",

}

TY - JOUR

T1 - Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

AU - Buch, Maya

PY - 2023/4/1

Y1 - 2023/4/1

U2 - 10.1136/ard-2022-223406

DO - 10.1136/ard-2022-223406

M3 - Letter

SN - 0003-4967

VL - 82

SP - 575

EP - 577

JO - Annals of Rheumatic Diseases

JF - Annals of Rheumatic Diseases

IS - 4

ER -